US2004131667A1PendingUtilityA1
Liposomal analgesic formulation and use
Est. expiryDec 20, 2022(expired)· nominal 20-yr term from priority
A61K 31/685A61K 31/355A61K 45/06A61K 31/196A61K 9/127A61K 31/195A61K 9/0017
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention provides methods and compositions for the treatment of lameness, navicular syndrome, osteoarthritis, or combinations thereof in horses.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method for treating lameness in a horse comprising topically administering to the horse a formulation comprising:
(a) about 0.1% to about 5% diclofenac; and (b) about 0.5% to about 20% phospholipids; whereby lameness in the horse is treated.
2 . The method of claim 1 , wherein the formulation further comprises about 0.1% to about 10% vitamin E.
3 . The method of claim 1 , wherein the formulation further comprises about 1% to about 20% alkylane glycol; and about 1% to about 50% (C 1 -C 6 ) alcohol.
3 . The method of claim 1 , wherein the formulation comprises:
(a) about 1% diclofenac salt, (b) about 5% propylene glycol, (c) about 6% ethanol, (d) about 1% vitamin E acetate, (e) about 10% phospholipid, and (f) about 77% water.
4 . The method of claim 1 , wherein the formulation comprises about 2 to about 10 micron liposomes.
5 . The method of claim 1 , wherein the formulation is topically administered twice daily.
6 . The method of claim 1 , wherein about 20 mg to about 120 mg of diclofenac is applied as a single dose to the horse.
7 . The method of claim 1 , wherein about 70 mg to about 80 mg of diclofenac is applied as a single dose to the horse.
8 . The method of claim 5 , wherein two doses per day are applied to the horse for at least about three days.
9 . The method of claim 2 , wherein the vitamin E is a C 2 -C 6 ester of vitamin E.
10 . The method of claim 2 , wherein the vitamin E is vitamin E acetate.
11 . The method claim 1 , wherein the diclofenac is a diclofenac salt.
12 . The method of claim 3 , wherein the alkylane glycol is propylene glycol.
13 . The method of claim 3 , wherein the C 1 -C 6 alcohol is ethanol.
14 . A method for treating osteoarthritis in a horse comprising topically administering to a horse a formulation comprising:
(a) about 1% to about 5% diclofenac; and (b) about 0.5% to about 20% phospholipids; whereby osteoarthritis in the horse is treated.
15 . The method of claim 14 , wherein the formulation further comprises about 0.1% to about 10% vitamin E.
16 . The method of claim 14 , wherein the formulation further comprises about 1% to about 20% alkylane glycol; and about 1% to about 50% (C 1 -C 6 ) alcohol.
17 . The method of claim 14 , wherein the formulation comprises:
(a) about 1% diclofenac salt, (b) about 5% propylene glycol, (c) about 6% ethanol, (d) about 1% vitamin E acetate, (e) about 10% phospholipid, and (g) about 77% water.
18 . The method of claim 14 , wherein the formulation comprises about 2 to about 10 micron liposomes.
19 . The method of claim 14 , wherein the formulation is topically administered twice daily.
20 . The method of claim 14 , wherein about 20 mg to about 120 mg of diclofenac is applied as a single dose to the horse.
21 . The method of claim 14 , wherein about 70 mg to about 80 mg of diclofenac is applied as a single dose to the horse.
22 . The method of claim 19 , wherein two doses per day are applied to the horse for at least about three days.
23 . The method of claim 15 , wherein the vitamin E is a C 2 -C 6 ester of vitamin E.
24 . The method of claim 15 , wherein the vitamin E is vitamin E acetate.
25 . The method claim 14 , wherein the diclofenac is a diclofenac salt.
26 . The method of claim 16 , wherein the alkylane glycol is propylene glycol.
27 . The method of claim 16 , wherein the C 1 -C 6 alcohol is ethanol.
28 . A method for treating navicular syndrome in a horse comprising topically administering to the a horse a formulation comprising:
(a) about 0.1% to about 5% diclofenac; and (b) about 0.5% to about 20% phospholipids; whereby navicular syndrome in the horse is treated.
29 . The method of claim 28 , wherein the formulation further comprises about 0.1% to about 10% vitamin E.
30 . The method of claim 28 , wherein the formulation further comprises about 1% to about 20% alkylane glycol; and about 1% to about 50% (C 1 -C 6 ) alcohol.
31 . The method of claim 28 , wherein the formulation comprises:
(a) about 1% diclofenac salt, (b) about 5% propylene glycol, (c) about 6% ethanol, (d) about 1% vitamin E acetate, (e) about 10% phospholipid, and (h) about 77% water.
32 . The method of claim 28 , wherein the formulation comprises about 2 to about 10 micron liposomes.
33 . The method of claim 28 , wherein the formulation is topically administered twice daily.
34 . The method of claim 28 , wherein about 20 mg to about 120 mg of diclofenac is applied as a single dose to the horse.
35 . The method of claim 28 , wherein about 70 mg to about 80 mg of diclofenac is applied as a single dose to the horse.
36 . The method of claim 33 , wherein two doses per day are applied to the horse for at least about three days.
37 . The method of claim 29 , wherein the vitamin E is a C 2 -C 6 ester of vitamin E.
38 . The method of claim 29 , wherein the vitamin E is vitamin E acetate.
39 . The method claim 28 , wherein the diclofenac is a diclofenac salt.
40 . The method of claim 30 , wherein the alkylane glycol is propylene glycol.
41 . The method of claim 30 , wherein the C 1 -C 6 alcohol is ethanol.Join the waitlist — get patent alerts
Track US2004131667A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.